Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (April 2012)

56 slides from Adocia SA's investor presentation, April 2012

  1. Slide 1: Investor presentation April 2012

    Slide 1: Investor presentation April 2012

    Investor presentation April 2012

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This document has been prepared by Adocia (the "Company") solely for use at the presentations organized with investors in connection with the Company's planned initial public offering and the offering to investors in France and outside France (the "Offering"). This document is provided fo

  3. Slide 3: Speakers

    Slide 3: Speakers

    Speakers Gérard SOULA Valérie DANAGUEZIAN Olivier SOULA Chairman and CEO CFO R&D Director Ph.D in Organic Chemistry, MBA ISC graduate Ph.D, MBA Founder of Flamel Technologies Former Head of R&D controlling, Aventis Former Director of the Nanotechnologies Pasteur Lyon Department, Flamel Technologies

  4. Slide 4: ADOCIA: Innovative Medicine for Everyone, Everywhere

    Slide 4: ADOCIA: Innovative Medicine for Everyone, Everywhere

    ADOCIA: “Innovative Medicine for Everyone, Everywhere” 1 Using approved therapeutic proteins … 2 … to license to big pharmas… 3 ... in combination with an innovative proprietary technology: BioChaperone®… 4 … at competitive prices compared to existing treatments… 5 … for developed and emerging count

  5. Slide 5: ADOCIA in brief

    Slide 5: ADOCIA in brief

    ADOCIA in brief Ø A biotechnology company developping innovative formulations with already-approved proteins − Listed on the regulated market of NYSE Euronext in Paris in February 2012 with €27.4 million raised Ø A unique operational technology, BioChaperone® platform, protected by 19 patent applica

  6. Slide 6: ADOCIA IPO: accelerating the company's development

    Slide 6: ADOCIA IPO: accelerating the company's development

    ADOCIA IPO: accelerating the company’s development Ø First IPO on the regulated market of NYSE Euronext in Paris this year – A total of €27,4 million raised – Market cap of approx. €90 million Ø « Top 5 » largest biotechnology companies listed in Paris Ø Additional means to accelerate the company’s

  7. Slide 7: A business model which requires low capital-intensive budgets

    Slide 7: A business model which requires low capital-intensive budgets

    A business model which requires low capital-intensive budgets Ø Innovation until the “Proof of Concept” established on human Ø The aim is to license innovative products to major players of pharmaceutical industry − Up-front and milestone payments − Transfer of the full clinical development to partne

  8. Slide 8: Summary

    Slide 8: Summary

    Summary Innovation dedicated to regenerative medicine 1 and chronic disease 2 Product breakthroughs 3 Financials 4 Why investing? Strategy and assets 5 Appendices 8

  9. Slide 9: Innovation dedicated to regenerative medicine and chronic disease

    Slide 9: Innovation dedicated to regenerative medicine and chronic disease

    Innovation dedicated 1 to regenerative medicine and chronic disease 9

  10. Slide 10: BioChaperone: a major technological leap

    Slide 10: BioChaperone: a major technological leap

    BioChaperone®: a major technological leap BioChaperone®, polysaccharide derivative, mimics the properties of heparin without anti-coagulation activity Ø BioChaperone® forms molecular complexes with therapeutic proteins... Ø ... to improve their efficacy : − Increase in solubility − Protection agains

  11. Slide 11: BioChaperone: an answer to the rise of therapeutic proteins

    Slide 11: BioChaperone: an answer to the rise of therapeutic proteins

    BioChaperone®: an answer to the rise of therapeutic proteins Ø BioChaperone® polymers have been customised for three classes of proteins Growth factors Hormones Monoclonal antibodies PDGF-BB Insulin Immunoglobulin Regenerative medicine Chronic disease BioChaperone®: a versatile technological platfor

  12. Slide 12: BioChaperone: a well protected technological platform

    Slide 12: BioChaperone: a well protected technological platform

    BioChaperone®: a well protected technological platform Ø An active intellectual property protection strategy Patents on BioChaperone® Patents on BioChaperone® Patents on therapeutic polymers protein complexes applications 9 patent applications 5 patent applications 5 patent applications Ø Internatio

  13. Slide 13: From innovation to pharmaceutical development

    Slide 13: From innovation to pharmaceutical development

    From innovation… to pharmaceutical development Ø Development through capital equity with a focus on 2 areas of therapeutic applications − The wound-healing market: diabetic foot ulcers (Phase II completed) • A market estimated at $3 billion(1) − The treatment of diabetes through insulin therapy (1 i

  14. Slide 14: Example: diabetes, a fast-growing market

    Slide 14: Example: diabetes, a fast-growing market

    Example: diabetes, a fast-growing market(1) Growing markets with Explosion of high value emerging added markets ADOCIA has integrated the constraints of two very different markets 14

  15. Slide 15: A strategy adapted to each market

    Slide 15: A strategy adapted to each market

    A strategy adapted to each market Our potential partners are already engaged in such a dual strategy Ø Developed countries: a “Value” strategy − Markets driven by prices − Still a strong demand for innovative best-in-class products with an acceptable extra cost Ø Emerging countries: a “Volume” strat

  16. Slide 16: Product breakthroughs

    Slide 16: Product breakthroughs

    Product breakthroughs 1 Wound healing 2 2 Insulin therapy 3 Formulation of monoclonal antibodies 16

  17. Slide 17: Product breakthroughs: Wound healing

    Slide 17: Product breakthroughs: Wound healing

    Product breakthroughs 1 Wound healing 2 17

  18. Slide 18: ADOCIA's 1st application in Diabetic Foot Ulcer

    Slide 18: ADOCIA's 1st application in Diabetic Foot Ulcer

    The wound healing market: 1 ADOCIA’s 1st application in Diabetic Foot Ulcer (DFU) Ø Diabetic Foot Ulcer − Reaching deep tissues of the foot − Consequence of the destructive effects of diabetes on nerves and arterial circulation within lower members Ø 15% of diabetics worldwide will develop a foot ul

  19. Slide 19: Treatments for diabetic foot ulcers

    Slide 19: Treatments for diabetic foot ulcers

    1 Treatments for diabetic foot ulcers Product Regranex® Gel Fiblast® spray Company Healthpoint biotherapeutics Kaken (Japan) + Olympus Marketed in Japan Status Amputation rate reduced by 30% Phase III in Europe Formulation from PDGF-BB growth factor FGF-2 fibroblast Technology growth factor (approve

  20. Slide 20: BioChaperone PDGF-BB: treating diabetic foot ulcers (1/3)

    Slide 20: BioChaperone PDGF-BB: treating diabetic foot ulcers (1/3)

    1 BioChaperone® PDGF-BB: treating diabetic foot ulcers (1/3) Ø Treatment of diabetic foot ulcer with an innovative BioChaperone® polymer associated with the PDGF-BB growth factor (Platelet Derivative Growth Factor) Ø Results of the Phase II clinical trial in India on 195 patients Regranex® vs. BioCh

  21. Slide 21: BioChaperone PDGF-BB: treating diabetic foot ulcer (2/3)

    Slide 21: BioChaperone PDGF-BB: treating diabetic foot ulcer (2/3)

    1 BioChaperone® PDGF-BB: treating diabetic foot ulcer (2/3) Week 0 Week 3 Week 6 Ø 3 factors of improvement for ADOCIA’s indication – Cost: dosage of the PDGF-BB divided by 3 compared to that of Regranex® – Compliance: one application every 2 days, compared to once a day with Regranex® – Ease of use

  22. Slide 22: BioChaperone PDGF-BB: treating diabetic foot ulcer (3/3)

    Slide 22: BioChaperone PDGF-BB: treating diabetic foot ulcer (3/3)

    1 BioChaperone® PDGF-BB: treating diabetic foot ulcer (3/3) Ø Upcoming clinical trials conducted by ADOCIA − 2012 • Q3: launch of a Phase III in India − 2013 • Q2: launch of a Phase III in Europe • Q2: launch of a Phase III in the US – 2014 • Q1: filing of a NDA for product launch in India 1st marke

  23. Slide 23: BioChaperone PDGF-BB: future developments

    Slide 23: BioChaperone PDGF-BB: future developments

    1 BioChaperone® PDGF-BB: future developments Ø Venous ulcers − Chronic skin wound that fails to heal spontaneously because of the improper functioning of venous valves − 1% of the population will suffer from at least one venous ulcer during their lives. A 12-month recurrence rate of up to 69%(1) (2)

  24. Slide 24: Product breakthroughs: Insulin therapy

    Slide 24: Product breakthroughs: Insulin therapy

    Product breakthroughs 2 Insulin therapy 2 24

  25. Slide 25: Diabetes: a blood sugar disorder

    Slide 25: Diabetes: a blood sugar disorder

    Diabetes: a blood sugar disorder Ø Diabetes: uncapacity of the human body to regulate blood sugar level − Blood sugar level control is normally done by insulin − This control fails for a diabetic, because of: • Lack of insulin production: type 1 diabetes, called insulin-dependent (10% of diabetics)

  26. Slide 26: Insulin therapy: restrictive and complex vital treatment

    Slide 26: Insulin therapy: restrictive and complex vital treatment

    2 Insulin therapy: restrictive and complex vital treatment Ø Insulin is THE treatment for this condition Ø Current insulin therapies rely on many products and medical devices − Long acting, Fast acting or Premix insulin Global diabetes care market by treatment class − Pen injector, needle or pump −

  27. Slide 27: Insulin therapy: a $17.2 billion market

    Slide 27: Insulin therapy: a $17.2 billion market

    2 Insulin therapy: a $17.2 billion market(1) Ø A huge market with solid growth over 2011 - 2030 − An increasing number of diabetics: from 366 million to 552 million people (+51%) (2) − Serious or lethal complications: 3.4 million deaths in 2004 around the world are thought to be associated with diab

  28. Slide 28: A dynamic and growing market

    Slide 28: A dynamic and growing market

    2 A dynamic and growing market Ø Human insulin market: $3.1 billion - 17% of the insulin-therapy market(1) Ø Insulin analog market: $14.2 billion(1) Prandial treatment Basal treatment Prandial – Basal treatment (Fast Acting) (Long Acting) (Medium-term and/or Premix) Single injection for both Regulat

  29. Slide 29: BioChaperone Prandial Insulin: strategic positioning

    Slide 29: BioChaperone Prandial Insulin: strategic positioning

    2 BioChaperone® Prandial Insulin: strategic positioning Ø Project n°1 – Human insulin Ø Project n°2 – Insulin analog Ø Humalog® Ø NovoLog® Ø Apidra® Ø Project n°1 – BioChaperone®-Human insulin Ø Project n°2 - BioChaperone®-Analog insulin BioChaperone® could provide a unique property to Prandial Insu

  30. Slide 30: Project n°1 – HinsBet: results of the Phase I clinical trial

    Slide 30: Project n°1 – HinsBet: results of the Phase I clinical trial

    2 Project n°1 – HinsBet®: results of the Phase I clinical trial Ø HinsBet® (BioChaperone®-Human insulin) was compared to a fast acting analog (NovoLog) and to human insulin (Actrapid) in a Phase I trial on 12 healthy volunteers (Germany) 14,0 12,0 Insulin ® HinsBet BC 10,0 Regular Insulin ActRapid ®

  31. Slide 31: BioChaperone Prandial Insulin strategic positioning

    Slide 31: BioChaperone Prandial Insulin strategic positioning

    2 BioChaperone® Prandial Insulin strategic positioning BioChaperone® - Human insulin EFFICACY OF THE TREATMENT Ø Next steps − Q4 2012: launch of a Phase BioChaperone ® IIa clinical trial with an optimised product that Fast acting Human Insulin is more effective on type 1 Fast diabetics acting Analog

  32. Slide 32: Project n°2 – BioChaperone-Insulin analog: preclinical results

    Slide 32: Project n°2 – BioChaperone-Insulin analog: preclinical results

    2 Project n°2 – BioChaperone®-Insulin analog: preclinical results Ø BioChaperone®-Insulin analog was compared to Insulin Analog in an established preclinical model correlated to humans, pig Time since injection (minutes) BioChaperone®-Insulin analog has a hypoglycaemic action faster and shorter than

  33. Slide 33: First license agreement on ultra-fast-acting insulin analog with a big pharma

    Slide 33: First license agreement on ultra-fast-acting insulin analog with a big pharma

    First license agreement on «ultra-fast-acting insulin analog» with 2 a big pharma Ø In December 2011, ADOCIA signed a license agreement with a major pharmaceutical group. This agreement deals with the development and the marketing of a fast-acting insulin analog with BioChaperone® technology Ø Terms

  34. Slide 34: BioChaperone Prandial Insulin strategic positioning

    Slide 34: BioChaperone Prandial Insulin strategic positioning

    2 BioChaperone® Prandial Insulin strategic positioning BioChaperone® - Insulin Analog EASE OF USE AND EFFICACY OF THE TREATMENT BioChaperone ® Ultra-fast acting Analogs Fast acting Analogs PRICE ADOCIA has engaged active collaboration with one of the major insulin pharmaceutical groups 34

  35. Slide 35: Project n°3 – BioChaperone-Insulin Combo: post Premix

    Slide 35: Project n°3 – BioChaperone-Insulin Combo: post Premix

    2 Project n°3 – BioChaperone®-Insulin Combo: post Premix Ø Premix properties: ensure insulin therapy with one single product Ø Lantus’ market: $4.6 billion NovoMix 30® SINGLE INJECTION AFTER HOMOGENISATION BioChaperone® Lantus Insulin Analog BioChaperone® Combo BC Combo SINGLE INJECTION BioChaperone

  36. Slide 36: BioChaperone-Insulin Combo: preclinical results

    Slide 36: BioChaperone-Insulin Combo: preclinical results

    2 BioChaperone®-Insulin Combo: preclinical results Ø BioChaperone®-Insulin Combo (BioChaperone® Lantus Apidra) was compared to a double injection of Lantus and Apidra (Lantus Apidra) in an established preclinical model correlated to humans, dog Time since injection (min) long acting + fast acting Bi

  37. Slide 37: BioChaperone-Insulin Combo strategic positioning

    Slide 37: BioChaperone-Insulin Combo strategic positioning

    2 BioChaperone®-Insulin Combo strategic positioning BioChaperone® -Insulin Combo EASE OF USE AND EFFICACY OF THE TREATMENT Adocia’s Ø Next step BioChaperone® Insulin Combo − Q4 2012: launch of a Phase I clinical trial Premix PRICE Our priority is to partner this project with a big pharma 37

  38. Slide 38: Product breakthroughs: Formulation of monoclonal antibodies

    Slide 38: Product breakthroughs: Formulation of monoclonal antibodies

    Product breakthroughs 3 Formulation of monoclonal antibodies 2 38

  39. Slide 39: BioChaperone mAbs: innovative monoclonal antibody formulations

    Slide 39: BioChaperone mAbs: innovative monoclonal antibody formulations

    3 BioChaperone® mAbs: innovative monoclonal antibody formulations Ø Monoclonal antibodies • Benchmark drugs in the treatment of numerous serious pathologies (chronic inflammatory disease, oncology) • Products with the highest growth in the pharma sector: a market estimated at $32 billion in 2008...

  40. Slide 40: ADOCIA: a solid and diversified product portfolio

    Slide 40: ADOCIA: a solid and diversified product portfolio

    ADOCIA: a solid and diversified product portfolio In Vitro Preclinical Clinical Products Phase I Phase II Phase III 1 BioChaperone® PDGF – wound healing Treatment of diabetic foot ulcers Treatment of venous ulcers Treatment of bedsores and burns 2 BioChaperone® Insulin - diabetes Fast Acting BioChap

  41. Slide 41: Financials

    Slide 41: Financials

    ADO C IA ®) Financials innovative medicine for everyone, everywhere

  42. Slide 42: ADOCIA: key figures

    Slide 42: ADOCIA: key figures

    ADOCIA: key figures Ø 2011 revenues: €1,6 million (€0,1 million in 2010) – Operating income up 75% – Impact of collaboration agreements, incl. on monoclonal antibodies – First license revenues with the license agreement on a fast-acting insulin analog Ø 2011 operating expenses: €9,7 million (€6,7 mi

  43. Slide 43: ADOCIA: P&L statement

    Slide 43: ADOCIA: P&L statement

    ADOCIA: P&L statement (in thousands €) - IFRS 12/31/2011 12/31/2010 Revenues 1 551 111 Other revenues 2 236 2 036 Total revenues 3 788 2 147 Operating expenses (excl. depreciations and -9 711 -6 683 amortization) Depreciations and amortization -151 -101 EBIT (6 074) (4 637) Other operating revenues

  44. Slide 44: ADOCIA: Condensed balance sheet

    Slide 44: ADOCIA: Condensed balance sheet

    ADOCIA: Condensed balance sheet (in thousands €) - IFRS 12/31/2011 12/31/2010 Non-current assets 564 706 Incl. laboratory equipment 378 475 Incl. other tangible assets 179 161 ASSETS Current assets 17 072 14 357 Incl. trade and other receivables 8 039 3 Incl. cash and cash equivalents 5 905 12 024 I

  45. Slide 45: ADOCIA: Cash flow

    Slide 45: ADOCIA: Cash flow

    ADOCIA: Cash flow (in thousands €) - IFRS 12/31/2011 12/31/2010 Net cash provided by or used for operations -6 217 -4 956 Net cash provided by or used for investment activities -155 -137 Net cash provided by or used for financing activities 252 4 418 Changes in net cash -6 119 -674 Cash at January 1

  46. Slide 46: Shareholding structure

    Slide 46: Shareholding structure

    Shareholding structure Shareholding structure (Feb. 2012) A solid and diversified shareholding structure 46

  47. Slide 47: Why investing? Strategy and assets

    Slide 47: Why investing? Strategy and assets

    Why investing? 4 Strategy and assets 47

  48. Slide 48: ADOCIA: a virtuous and ambitious growth model

    Slide 48: ADOCIA: a virtuous and ambitious growth model

    ADOCIA: a virtuous and ambitious growth model Collaborative Products aimed to be BioChaperone® finalised agreements blockbusters and operational and licenses with a global target 1 major license License revenue Potential powerful agreement without waiting for partners products to be Substantial roya

  49. Slide 49: ADOCIA's strategy

    Slide 49: ADOCIA's strategy

    ADOCIA’s strategy Ø Become a world leader in the formulation of therapeutic proteins… – Growth factor – Insulin – Monoclonal antibodies Ø … by signing partnerships with big pharmas in the corresponding therapeutic domains An ambitious “innovative leader” strategy 49

  50. Slide 50: ADOCIA: considerable assets

    Slide 50: ADOCIA: considerable assets

    ADOCIA: considerable assets MAJOR TECHNOLOGICAL LEAP Ø BioChaperone®, ADOCIA’s proprietary technological platform VERY SIGNIFICANT Ø Promising clinical results in 2 therapeutic domains worth billions of dollars: the treatment DEVELOPMENT POTENTIAL of chronic wounds and insulin therapy for diabetes L

  51. Slide 51: ADOCIA: substantial short-term newsflow

    Slide 51: ADOCIA: substantial short-term newsflow

    ADOCIA: substantial short-term newsflow Ø Launch of a phase III study in Q3 2012 in India for the treatment of the diabetic foot ulcer with the PDGF-BB growth factor Ø Launch of a phase I study in Q3 2012 for the treatment of diabetes with fast-acting and slow-acting combo insulins Ø Launch of a sec

  52. Slide 52: Appendices

    Slide 52: Appendices

    A D 0 C I Q © Appendices innovative medicine for everyone, everywhere

  53. Slide 53: Notes

    Slide 53: Notes

    Notes 1. SHIRE, annoucement of May 17, 2011 for the acquisition of Advanced Biohealing Page 13 2. Business Insights. The Diabetes Market Outlook to 2016 – May2011 Page 14 1. Wild et al. Diabetes care, volume 27, number 5, 1047-1053 – 2004 1. Reiber GE. Diabetes foot care : financial implications and

  54. Slide 54: BioChaperone: the leading technology for regenerative medicine

    Slide 54: BioChaperone: the leading technology for regenerative medicine

    BioChaperone® : the leading technology for regenerative medicine Cellular therapy Gene therapy BioChaperone® Ø « Deliberate introduction of genetic material Ø « Transplant of stem cells so as to renew the within somatic human cells so as to repair a Ø « Association of an innovative polymer that func

  55. Slide 55: Strategy de Life Cycle Management on revealed markets

    Slide 55: Strategy de Life Cycle Management on revealed markets

    Strategy de Life Cycle Management on revealed markets Development Therapeutic benefit New Shorter time of New intellectual Reduction administration development property of dosage ways New formulation Innovative treatments using = approved proteins Improved efficacy Manufacturing process easily Lower

  56. Slide 56: Stock market: NYSE Euronext Paris – compartment C

    Slide 56: Stock market: NYSE Euronext Paris – compartment C

    • Stock market: NYSE Euronext Paris – compartment C • First listing day: 20 February 2012, at a share price of €15.88 • ISIN code: FR0011184241 • Mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP • Total number of shares: 6,181,776 • Sector: Pharmacy and biotechnology – ICB 4570 • Index: Next Biot

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks